Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.
Regeneron’s Obesity Trial With Novo Nordisk’s Wegovy Hits Lean Target
Where Today's News Shapes Tomorrow
December 16, 2025
Headlines
